# A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Source: https://onco.cc/trials/nct06844357/  
OnCo record `nct06844357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of tirapazamine in hepatocellular carcinoma, run by Zhejiang Raygene Pharmaceuticals Co., Ltd, now recruiting.

## Summary

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. is a phase 2/3 interventional study registered as NCT06844357 by Zhejiang Raygene Pharmaceuticals Co., Ltd, with 300 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-04-01. Interventions recorded: tirapazamine, Transarterial Embolization (TAE) and TACE.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06844357
- Phase: 2/3
- Setting: A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)
- Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06844357: https://clinicaltrials.gov/study/NCT06844357

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct06844357.json